EUVIMEDEUVIMED entdecken
Crossref

Multi‐modal models using fMRI , urine and serum biomarkers for classification and risk prognosis in diabetic kidney disease

Xian Shao iD, Huanqing Xu, Lianqin Chen, Pufei Bai, Haizhen Sun, Qian Yang, Ruixuan Chen, Queran Lin, Lihua Wang, Ying Li, Yao Lin, Pei Yu iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16572 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Xian Shao und 11 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Lab of Hormones and Development, Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute …. Hauptthemen laut MEDLINE: Biomarkers, Magnetic Resonance Imaging, Diabetic Nephropathies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Tianjin Science and Technology Major Special Project and Engineering Public Health Science and Technology Major Special Project, The Second Batch of High-Level Talents Selection Project in Health Industry in Tianjin, Science and Technology Project of Tianjin Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Functional magnetic resonance imaging (fMRI) is a powerful tool for non‐invasive evaluation of micro‐changes in the kidneys. This study aims to develop classification and prognostic models based on multi‐modal data.

Methods

A total of 172 participants were included, and high‐resolution multi‐parameter fMRI technology was employed to obtain T2‐weighted imaging (T2WI), blood oxygen level dependent (BOLD), and diffusion tensor imaging (DTI) sequence images. Based on clinical indicators, fMRI markers, serum and urine biomarkers (CD300LF, CST4, MMRN2, SERPINA1, l ‐glutamic acid dimethyl ester and phosphatidylcholine), machine learning algorithms were applied to establish and validate classification diagnosis models (Models 1–6) and risk‐prognostic models (Models A–E). Additionally, accuracy, sensitivity, specificity, precision, area under the curve (AUC) and recall were used to evaluate the predictive performance of the models.

Results

A total of six classification models were established. Model 5 (fMRI + clinical indicators) exhibited superior performance, with an accuracy of 0.833 (95% confidence interval [CI]: 0.653–0.944). Notably, the multi‐modal model incorporating image, serum and urine multi‐omics and clinical indicators (Model 6) demonstrated higher predictive performance, achieving an accuracy of 0.923 (95% CI: 0.749–0.991). Furthermore, a total of five prognostic models at 2‐year and 3‐year follow‐up were established. The Model E exhibited superior performance, achieving AUC values of 0.975 at the 2‐year follow‐up and 0.932 at the 3‐year follow‐up. Furthermore, Model E can identify patients with a high‐risk prognosis.

Conclusion

In clinical practice, the multi‐modal models presented in this study demonstrate potential to enhance clinical decision‐making capabilities regarding patient classification and prognosis prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersMagnetic Resonance ImagingDiabetic NephropathiesHumansMaleFemalePrognosisMiddle AgedAdultAgedDiffusion Tensor ImagingMachine LearningRisk Assessment

Stichwörter der Autor:innen

diabetic kidney diseasefunctional magnetic resonance imagingmachine learningmulti‐modal models

Substanzen

Biomarkers

Autor:innen und Institutionen

  • NHC Key Lab of Hormones and Development, Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin, China.
  • Division of Nephrology, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • School of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Clinical Research Design Division, Clinical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Univer…
  • WHO Collaborating Centre for Public Health Education and Training, School of Public Health, Department of Primary Care and Public Health, Faculty of Medicine, Imperial College London, London, UK.
  • Department of Nephrology & Blood Purification Center, The Second Hospital of Tianjin Medical University, Tianjin, China.

ORCID-Profile: Xian Shao, Pei Yu

Förderung

  • Tianjin Science and Technology Major Special Project and Engineering Public Health Science and Technology Major Special Project
  • The Second Batch of High-Level Talents Selection Project in Health Industry in Tianjin
  • Science and Technology Project of Tianjin Health Commission
  • Tianjin Natural Science Foundation Key Projects
  • President's Fund of Nanfang Hospital, Southern Medical University
  • Tianjin Key Medical Discipline (Specialty) Construct Project
  • Scientific Research Funding of Tianjin Medical University Chu Hsien-I Memorial Hospital
  • First Level Leading Talent Project of 123 Climbing Plan for Clinical Talents of Tianjin Medical University

Zitieren

APA

Shao, X., Xu, H., Chen, L., Bai, P., Sun, H., Yang, Q., Chen, R., Lin, Q., Wang, L., Li, Y., Lin, Y., & Yu, P. (2025). Multi‐modal models using fMRI , urine and serum biomarkers for classification and risk prognosis in diabetic kidney disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16572

Vancouver

Shao X, Xu H, Chen L, Bai P, Sun H, Yang Q, et al. Multi‐modal models using fMRI , urine and serum biomarkers for classification and risk prognosis in diabetic kidney disease. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16572

BibTeX
@article{Shao2025,
  author = {Shao, Xian and Xu, Huanqing and Chen, Lianqin and Bai, Pufei and Sun, Haizhen and Yang, Qian and Chen, Ruixuan and Lin, Queran and Wang, Lihua and Li, Ying and Lin, Yao and Yu, Pei},
  title = {Multi‐modal models using fMRI , urine and serum biomarkers for classification and risk prognosis in diabetic kidney disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16572}
}
Kostenlos starten →